JP2024504377A5 - - Google Patents
Info
- Publication number
- JP2024504377A5 JP2024504377A5 JP2023544331A JP2023544331A JP2024504377A5 JP 2024504377 A5 JP2024504377 A5 JP 2024504377A5 JP 2023544331 A JP2023544331 A JP 2023544331A JP 2023544331 A JP2023544331 A JP 2023544331A JP 2024504377 A5 JP2024504377 A5 JP 2024504377A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140674P | 2021-01-22 | 2021-01-22 | |
| US63/140,674 | 2021-01-22 | ||
| US202163217624P | 2021-07-01 | 2021-07-01 | |
| US63/217,624 | 2021-07-01 | ||
| US202163231559P | 2021-08-10 | 2021-08-10 | |
| US63/231,559 | 2021-08-10 | ||
| PCT/US2022/013323 WO2022159712A1 (en) | 2021-01-22 | 2022-01-21 | Compounds and methods for reducing dux4 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504377A JP2024504377A (ja) | 2024-01-31 |
| JPWO2022159712A5 JPWO2022159712A5 (https=) | 2025-01-24 |
| JP2024504377A5 true JP2024504377A5 (https=) | 2025-01-24 |
Family
ID=82549881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544331A Pending JP2024504377A (ja) | 2021-01-22 | 2022-01-21 | Ｄｕｘ４の発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240336915A1 (https=) |
| EP (1) | EP4281084A4 (https=) |
| JP (1) | JP2024504377A (https=) |
| WO (1) | WO2022159712A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4370678A2 (en) * | 2021-07-14 | 2024-05-22 | Mirecule, Inc. | Oligonucleotides and compositions thereof for neuromuscular disorders |
| EP4590308A2 (en) * | 2022-09-23 | 2025-07-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing mecp2 expression |
| JP2025532127A (ja) | 2022-09-23 | 2025-09-29 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｍｅｃｐ２発現を低減する化合物及び方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225034A1 (en) * | 2010-09-02 | 2012-09-06 | Universite De Mons | Agents useful in treating facioscapulohumeral muscular dystrophy |
| AU2012286994B2 (en) * | 2011-07-25 | 2017-08-10 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of DUX4 |
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| EP3353301A1 (en) * | 2015-09-21 | 2018-08-01 | Association Institut de Myologie | Antisense oligonucleotides and uses thereof |
| CA3099522C (en) * | 2017-09-19 | 2024-10-08 | The Governors Of The University Of Alberta | GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY |
| AU2019218987B2 (en) * | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| US20220195431A1 (en) * | 2019-02-22 | 2022-06-23 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn3 expression |
| TW202104595A (zh) * | 2019-03-29 | 2021-02-01 | 日商田邊三菱製藥股份有限公司 | 用來調節ｄｕｘ４的表現之化合物、方法及醫藥組成物 |
-
2022
- 2022-01-21 US US18/262,438 patent/US20240336915A1/en active Pending
- 2022-01-21 JP JP2023544331A patent/JP2024504377A/ja active Pending
- 2022-01-21 EP EP22743253.1A patent/EP4281084A4/en active Pending
- 2022-01-21 WO PCT/US2022/013323 patent/WO2022159712A1/en not_active Ceased